388 related articles for article (PubMed ID: 26993225)
1. Myocardial reverse remodeling: how far can we rewind?
Rodrigues PG; Leite-Moreira AF; Falcão-Pires I
Am J Physiol Heart Circ Physiol; 2016 Jun; 310(11):H1402-22. PubMed ID: 26993225
[TBL] [Abstract][Full Text] [Related]
2. Prevention of heart failure with preserved ejection fraction (HFpEF): reexamining microRNA-21 inhibition in the era of oligonucleotide-based therapeutics.
Ben-Nun D; Buja LM; Fuentes F
Cardiovasc Pathol; 2020; 49():107243. PubMed ID: 32629211
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a mouse model of obesity-related fibrotic cardiomyopathy that recapitulates features of human heart failure with preserved ejection fraction.
Alex L; Russo I; Holoborodko V; Frangogiannis NG
Am J Physiol Heart Circ Physiol; 2018 Oct; 315(4):H934-H949. PubMed ID: 30004258
[TBL] [Abstract][Full Text] [Related]
4. The effects of liraglutide and dapagliflozin on cardiac function and structure in a multi-hit mouse model of heart failure with preserved ejection fraction.
Withaar C; Meems LMG; Markousis-Mavrogenis G; Boogerd CJ; Silljé HHW; Schouten EM; Dokter MM; Voors AA; Westenbrink BD; Lam CSP; de Boer RA
Cardiovasc Res; 2021 Jul; 117(9):2108-2124. PubMed ID: 32871009
[TBL] [Abstract][Full Text] [Related]
5. Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial.
Shah AM; Shah SJ; Anand IS; Sweitzer NK; O'Meara E; Heitner JF; Sopko G; Li G; Assmann SF; McKinlay SM; Pitt B; Pfeffer MA; Solomon SD;
Circ Heart Fail; 2014 Jan; 7(1):104-15. PubMed ID: 24249049
[TBL] [Abstract][Full Text] [Related]
6. Drugs That Ameliorate Epicardial Adipose Tissue Inflammation May Have Discordant Effects in Heart Failure With a Preserved Ejection Fraction as Compared With a Reduced Ejection Fraction.
Packer M
J Card Fail; 2019 Dec; 25(12):986-1003. PubMed ID: 31541742
[TBL] [Abstract][Full Text] [Related]
7. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
Slee A; Saad M; Saksena S
J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin ligase WWP1 contributes to shifts in matrix proteolytic profiles and a myocardial aging phenotype with diastolic heart.
Matesic LE; Freeburg LA; Snyder LB; Duncan LA; Moore A; Perreault PE; Zellars KN; Goldsmith EC; Spinale FG
Am J Physiol Heart Circ Physiol; 2020 Oct; 319(4):H765-H774. PubMed ID: 32822210
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Prognostic Usefulness of Serum Insulin-Like Growth Factor-Binding Protein 7 in Patients With Heart Failure and Preserved Versus Reduced Left Ventricular Ejection Fraction.
Hage C; Bjerre M; Frystyk J; Gu HF; Brismar K; Donal E; Daubert JC; Linde C; Lund LH
Am J Cardiol; 2018 Jun; 121(12):1558-1566. PubMed ID: 29622288
[TBL] [Abstract][Full Text] [Related]
10. Sudden death in heart failure with preserved ejection fraction and beyond: an elusive target.
Manolis AS; Manolis AA; Manolis TA; Melita H
Heart Fail Rev; 2019 Nov; 24(6):847-866. PubMed ID: 31147814
[TBL] [Abstract][Full Text] [Related]
11. Insight into the Pro-inflammatory and Profibrotic Role of Macrophage in Heart Failure With Preserved Ejection Fraction.
Shen JL; Xie XJ
J Cardiovasc Pharmacol; 2020 Sep; 76(3):276-285. PubMed ID: 32501838
[TBL] [Abstract][Full Text] [Related]
12. Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction.
Hahn VS; Knutsdottir H; Luo X; Bedi K; Margulies KB; Haldar SM; Stolina M; Yin J; Khakoo AY; Vaishnav J; Bader JS; Kass DA; Sharma K
Circulation; 2021 Jan; 143(2):120-134. PubMed ID: 33118835
[TBL] [Abstract][Full Text] [Related]
13. Cardiac Remodeling Biomarkers as Potential Circulating Markers of Left Ventricular Hypertrophy in Heart Failure with Preserved Ejection Fraction.
Mitic VT; Stojanovic DR; Deljanin Ilic MZ; Stojanovic MM; Petrovic DB; Ignjatovic AM; Stefanovic NZ; Kocic GM; Bojanic VV
Tohoku J Exp Med; 2020 Apr; 250(4):233-242. PubMed ID: 32295985
[TBL] [Abstract][Full Text] [Related]
14. Distinct Myocardial Targets for Diabetes Therapy in Heart Failure With Preserved or Reduced Ejection Fraction.
Paulus WJ; Dal Canto E
JACC Heart Fail; 2018 Jan; 6(1):1-7. PubMed ID: 29284577
[TBL] [Abstract][Full Text] [Related]
15. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
16. Atrial resynchronization therapy in patients with atrial fibrillation and heart failure with and without systolic left ventricular dysfunction: a pilot study.
Saksena S; Slee A; Saad M
J Interv Card Electrophysiol; 2018 Oct; 53(1):9-17. PubMed ID: 29987682
[TBL] [Abstract][Full Text] [Related]
17. Breakthroughs in the treatment of heart failure with mildly reduced and preserved ejection fraction.
Talha KM; Butler J
Clin Cardiol; 2022 Jun; 45 Suppl 1(Suppl 1):S31-S39. PubMed ID: 35789018
[TBL] [Abstract][Full Text] [Related]
18. Use of speckle tracking to assess heart failure with preserved ejection fraction.
Hiebert JB; Vacek J; Shah Z; Rahman F; Pierce JD
J Cardiol; 2019 Nov; 74(5):397-402. PubMed ID: 31303358
[TBL] [Abstract][Full Text] [Related]
19. Correlates and Prognostic Values of Appearance of L Wave in Heart Failure Patients With Preserved vs. Reduced Ejection Fraction.
Masai K; Mano T; Goda A; Sugahara M; Daimon A; Asakura M; Ishihara M; Masuyama T
Circ J; 2018 Aug; 82(9):2311-2316. PubMed ID: 30022769
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology and pathogenesis of heart failure with preserved ejection fraction.
Nair N
Rev Cardiovasc Med; 2020 Dec; 21(4):531-540. PubMed ID: 33387998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
